Loading…
Lobbying Spend
—
Filings
34
Firms Hired
3
Active Period
1999–2008
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Access to Life-Saving Medicine Act
2008 · fourth_quarter · Firm: MCKENNA, LONG & ALDRIDGE
Generic Issues - Biogenerics (S.1082; S.623)
Client expense: — · Firm income: $10,000
Matched citations: S.623
Access to Life-Saving Medicine Act
2008 · third_quarter · Firm: MCKENNA, LONG & ALDRIDGE
Generic Issues - Biogenerics (S.1082; S.623)
Client expense: — · Firm income: $10,000
Matched citations: S.623
Access to Life-Saving Medicine Act
2008 · second_quarter · Firm: MCKENNA, LONG & ALDRIDGE
Generic Issues - Biogenerics (S.1082; S.623)
Client expense: — · Firm income: $10,000
Matched citations: S.623
To amend title 35, United States Code, to allow the Director of the United States Patent and Trademark Office to accept late filings in certain cases of unintentional delay.
2008 · first_quarter · Firm: WINSTON & STRAWN LLP
Work toward implementation of Tax Treaty with Croatia; Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments; potential pharmaceutical offsets for S-CHIP extension; procedures for drug approval harmonizatoin in prospective trade agreements.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1778
Work toward implementation of Tax Treaty with Croatia; Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments; potential pharmaceutical offsets for S-CHIP extension; procedures for drug approval harmonizatoin in prospective trade agreements.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1908
Patient Protection and Innovative Biologic Medicines Act of 2007
2008 · first_quarter · Firm: WINSTON & STRAWN LLP
Work toward implementation of Tax Treaty with Croatia; Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments; potential pharmaceutical offsets for S-CHIP extension; procedures for drug approval harmonizatoin in prospective trade agreements.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1956
Food and Drug Administration Amendments Act of 2007
2008 · first_quarter · Firm: WINSTON & STRAWN LLP
Work toward implementation of Tax Treaty with Croatia; Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments; potential pharmaceutical offsets for S-CHIP extension; procedures for drug approval harmonizatoin in prospective trade agreements.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3580
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
2008 · first_quarter · Firm: WINSTON & STRAWN LLP
Work toward implementation of Tax Treaty with Croatia; Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments; potential pharmaceutical offsets for S-CHIP extension; procedures for drug approval harmonizatoin in prospective trade agreements.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 806
Work toward implementation of Tax Treaty with Croatia; Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments; potential pharmaceutical offsets for S-CHIP extension; procedures for drug approval harmonizatoin in prospective trade agreements.
Client expense: — · Firm income: $50,000
Matched citations: S.1145
Biologics Price Competition and Innovation Act of 2007
2008 · first_quarter · Firm: WINSTON & STRAWN LLP
Work toward implementation of Tax Treaty with Croatia; Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments; potential pharmaceutical offsets for S-CHIP extension; procedures for drug approval harmonizatoin in prospective trade agreements.
Client expense: — · Firm income: $50,000
Matched citations: S.1695
Preserve Access to Affordable Generics Act
2008 · first_quarter · Firm: WINSTON & STRAWN LLP
Work toward implementation of Tax Treaty with Croatia; Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments; potential pharmaceutical offsets for S-CHIP extension; procedures for drug approval harmonizatoin in prospective trade agreements.
Client expense: — · Firm income: $50,000
Matched citations: S.316
Access to Life-Saving Medicine Act
2008 · first_quarter · Firm: MCKENNA, LONG & ALDRIDGE
Generic Issues - Biogenerics (S.1082; S.623)
Client expense: — · Firm income: $10,000
Matched citations: S.623
Expanding Education for Military Families Act of 2003
2007 · year_end · Firm: WINSTON & STRAWN LLP
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: H.R. 2764
To ratify the authority of the Federal Trade Commission to establish a do-not-call registry.
2007 · year_end · Firm: WINSTON & STRAWN LLP
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: H.R. 3161
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: H.R. 1908
Patient Protection and Innovative Biologic Medicines Act of 2007
2007 · year_end · Firm: WINSTON & STRAWN LLP
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: H.R. 1956
Food and Drug Administration Amendments Act of 2007
2007 · year_end · Firm: WINSTON & STRAWN LLP
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: H.R. 3580
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
2007 · year_end · Firm: WINSTON & STRAWN LLP
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: H.R. 806
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: S.1145
Biologics Price Competition and Innovation Act of 2007
2007 · year_end · Firm: WINSTON & STRAWN LLP
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: S.1695
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008
2007 · year_end · Firm: WINSTON & STRAWN LLP
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: S.1859
Preserve Access to Affordable Generics Act
2007 · year_end · Firm: WINSTON & STRAWN LLP
Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; patent reform legislation (H.R. 1908 and S.1145); authorized generics (H.R. 806; S.1082); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 3580); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859; H.R. 2764); opposition to legislation proposing patent filing deadline
Client expense: — · Firm income: $100,000
Matched citations: S.316
Biologics Price Competition and Innovation Act of 2007
2007 · year_end · Firm: MCKENNA, LONG & ALDRIDGE
generic drug issues (S 1695)
Client expense: — · Firm income: $60,000
Matched citations: S 1695
To ratify the authority of the Federal Trade Commission to establish a do-not-call registry.
2007 · mid_year · Firm: WINSTON & STRAWN LLP
authorized generics (H.R. 806; S.1082); patent reform legislation (H.R. 1908 and S.1145); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 2900); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859); procedures for drug approval harmonization in prospective trade agreements. Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments;
Client expense: — · Firm income: $100,000
Matched citations: H.R. 3161
To amend title 35, United States Code, to allow the Director of the United States Patent and Trademark Office to accept late filings in certain cases of unintentional delay.
2007 · mid_year · Firm: WINSTON & STRAWN LLP
authorized generics (H.R. 806; S.1082); patent reform legislation (H.R. 1908 and S.1145); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 2900); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859); procedures for drug approval harmonization in prospective trade agreements. Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments;
Client expense: — · Firm income: $100,000
Matched citations: H.R. 1778
Source: Senate LDA